Hemiasterlin analog HTI-286 effect on docetaxel-resistant prostate cancer cell line
Summary:
Analysis of prostate cancer LNCaP cells treated with the chemotherapeutic agent docetaxel or the hemiasterlin analog HTI-286. Like docetaxel, HTI-286 disrupts microtubule dynamics. But unlike docetaxel, HT-286 exhibits reduced multidrug resistance.
Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A et al. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. Int J Cancer 2008 May 15;122(10):2368-76. PMID: 18240145
